Investigating a new treatment to prevent lung disease in premature infants
Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates
This study is testing a new medication called AVR-48 to see if it can help prevent lung problems in premature babies, aiming to improve their breathing and overall health.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ayuvis Research, INC. NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project ID | NIH-11074691 on NIH RePORTER |
What this research studies
This research focuses on developing a new medication, AVR-48, aimed at preventing bronchopulmonary dysplasia (BPD) in premature infants. The study will first assess the safety and how the drug is processed in the body, followed by a proof-of-concept phase to evaluate its effectiveness. By targeting inflammation and promoting lung development, AVR-48 could significantly improve respiratory function and survival rates in affected neonates. The research utilizes animal models to test the drug's impact on lung health and development.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants who are at risk of developing bronchopulmonary dysplasia due to mechanical ventilation.
Not a fit: Patients who are not premature or who do not require mechanical ventilation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly reduces the incidence of bronchopulmonary dysplasia in premature infants, improving their health outcomes.
How similar studies have performed: Previous research has shown promise in using macrophage modulators for similar conditions, indicating potential for success with this novel approach.
Where this research is happening
Fort Worth, United States
- Ayuvis Research, INC. — Fort Worth, United States (Active)
Researchers
- Principal investigator: Acharya, Suchismita — Ayuvis Research, INC.
- Study coordinator: Acharya, Suchismita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.